LONDON (Reuters) -Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal. Last ...

Hantavirus pulmonary infection is a disease caused by some hantaviruses, not the Pfizer-BioNTech COVID-19 vaccine, contrary ...

The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to ...

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its ...

The company said it would exit operations at some manufacturing plants in Germany and Singapore, and that as many as 1,860 ...

On its first-quarter 2026 conference call held on May 5, Pfizer PFE CEO Albert Bourla said the company expects a high ...

Those eager to discredit Pfizer's mRNA vaccine, which is safe and effective, exploited the cruise ship outbreak.

Last year, the High Court ruled that one of Moderna’s patents relating to the messenger RNA (mRNA) technology, which underpinned its COVID-19 vaccine, was valid and that Pfizer and BioNTech’s ...

Phase 3 clinical trial cohort of adults 65+ and 18-64 with at least one underlying risk condition shows at least a 4-fold increase in LP.8.1-neutralizing antibody titers after receiving the ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...